Already a DIA Member? Sign in. Not a member? Join.

Iniciar sesión

¿Ha olvidado su ID de usuario? or ¿Ha olvidado su contraseña?

Not a Member?

Create Account and Join

InterContinental San Francisco

05 nov 2018 7:00 a.m. - 06 nov 2018 3:00 p.m.

888 Howard Street, San Francisco, CA 94103

Real World Evidence Conference

This conference has reached maximum capacity.

Perspectiva general

Within the past few years there has been a lot of discussion on the generation and utilization of real world evidence (RWE). It is well-known that regulators use RWE to monitor post-market safety and to make regulatory decisions, Sponsors utilize it to support both clinical trial design and observational studies to generate treatment approaches, and healthcare systems collect and use RWE to substantiate coverage decisions. However, what are the ‘new and innovative’ RWE applications in today’s healthcare ecosystem? This conference will explore examples of unique applications of RWE, and describe novel ways stakeholders are leveraging RWE to advance healthcare knowledge and decision-making.

Featured

Want to learn more about Real World Evidence Conference? You've come to the right site!

Continuing Education

¿Quiénes deben asistir?

Professionals involved in:

  • Real World Evidence
  • Epidemiology
  • Policy
  • Regulatory Science

Objetivos de aprendizaje

At the conclusion of this conference, participants should be able to:

  • Explain how RWE can facilitate clinical trial design
  • Describe criteria in which RWE has been used for label expansion and discuss future applications 
  • Discuss appropriate uses for patient generated health data 
  • Identify areas where medical devices have successfully used RWE for regulatory decision-making 

Comité del programa

  • Jeff  Allen, PhD
    Jeff Allen, PhD President and Chief Executive Officer
    Friends of Cancer Research, United States
  • Brian  Bradbury, DrSc, MA
    Brian Bradbury, DrSc, MA Vice President, Center for Observational Research
    Amgen, United States
  • Paul M. Coplan, DrSc, MBA, MSc, FISPE
    Paul M. Coplan, DrSc, MBA, MSc, FISPE VP, Medical Device Epidemiology & Real-World Data Analytics
    Johnson & Johnson, United States
  • Jacqueline A. Corrigan-Curay, JD, MD
    Jacqueline A. Corrigan-Curay, JD, MD Principal Deputy Center Director, Center for Drug Evaluation and Research (CDER)
    FDA, United States
  • Nancy A Dreyer, PhD, MPH, FISPE
    Nancy A Dreyer, PhD, MPH, FISPE Founder
    Dreyer Strategies LLC, United States
  • Marni  Hall, PhD, MPH
    Marni Hall, PhD, MPH Vice President and General Manager, Global Regulatory Science and Strategy
    IQVIA, United States
  • James  Harnett, PharmD, MS
    James Harnett, PharmD, MS Executive Director, Health Economics and Outcomes Research
    Regeneron Pharmaceuticals, Inc. , United States
  • Sophie  Janssens
    Sophie Janssens Vice President, Global Head of Real World Evidence
    UCB Pharma, Inc, Belgium
  • Gabriela  Lavezzari, PhD, MBA
    Gabriela Lavezzari, PhD, MBA Senior Director, US R&D Policy and Scientific Affairs
    GlaxoSmithKline, United States
  • Debra  Schaumberg, DrSc, MPH
    Debra Schaumberg, DrSc, MPH Vice President and Global Head, Startegic Development Consulting Chair
    Evidera | PPD, United States
  • Mark  Stewart, PhD
    Mark Stewart, PhD Vice President, Science Policy
    Friends of Cancer Research, United States

Digital Learning Catalog

DIA Learning: eLearning Soultions
Download

¿Tiene una cuenta?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.